SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-024057
Filing Date
2016-08-11
Accepted
2016-08-11 16:01:59
Documents
61
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 NAVB-Q2-20160630 navb-10q_20160630.htm 10-Q 1745000
2 EX-31.1 navb-ex311_7.htm EX-31.1 10198
3 EX-32.1 navb-ex321_6.htm EX-32.1 5758
  Complete submission text file 0001564590-16-024057.txt   7384707

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT navb-20160630.xml EX-101.INS 1800237
5 XBRL TAXONOMY EXTENSION SCHEMA navb-20160630.xsd EX-101.SCH 45360
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20160630_cal.xml EX-101.CAL 51316
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20160630_def.xml EX-101.DEF 200805
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20160630_lab.xml EX-101.LAB 377187
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20160630_pre.xml EX-101.PRE 319599
Mailing Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017
Business Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 161824550
SIC: 2835 In Vitro & In Vivo Diagnostic Substances